Santhera Pharmaceuticals (SPHDF) News Today $11.70 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in QatarNovember 13, 2024 | markets.businessinsider.comSanthera: LIONHEART Study Confirms Vamorolone's Unique Role As Mineralocorticoid Receptor AntagonistOctober 1, 2024 | markets.businessinsider.comSanthera Pharmaceuticals Holding (SANN)September 27, 2024 | uk.investing.comSanthera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular DystrophySeptember 25, 2024 | finance.yahoo.comSanthera Pharma H1 Net Loss Narrows, Revenues ClimbSeptember 12, 2024 | markets.businessinsider.comSanthera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern EuropeSeptember 10, 2024 | finance.yahoo.comSanthera Pharma Partners With GENESIS Pharma For AGAMREE Distribution In Central And Eastern EuropeSeptember 10, 2024 | nasdaq.comSanthera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026August 13, 2024 | finance.yahoo.comSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2023May 28, 2024 | finanznachrichten.deSanthera Publishes Annual Report 2023May 28, 2024 | finance.yahoo.comSanthera : Vamorolone NDA Accepted For Priority Review By China' NMPA In Duchenne Muscular DystrophyMarch 27, 2024 | markets.businessinsider.comSanthera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPAMarch 27, 2024 | finance.yahoo.comSanthera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in NeurologyFebruary 14, 2024 | finance.yahoo.comSanthera Pharmaceuticals Holding AG 0QN1February 3, 2024 | morningstar.comSanthera Pharmaceuticals Holding AG (SANN.SW)January 31, 2024 | finance.yahoo.comSanthera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular DystrophyJanuary 15, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)January 12, 2024 | markets.businessinsider.comSanthera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United KingdomJanuary 12, 2024 | finance.yahoo.comSanthera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular DystrophyDecember 18, 2023 | finance.yahoo.comSanthera Appoints Executive Committee Members as it Transitions into Commercial StageDecember 7, 2023 | finance.yahoo.comSanthera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophyOctober 27, 2023 | finance.yahoo.comUS FDA approves Santhera's Duschenne drugOctober 26, 2023 | reuters.comSanthera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular DystrophyOctober 13, 2023 | markets.businessinsider.comPositive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD TreatmentOctober 13, 2023 | markets.businessinsider.comSanthera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophyOctober 13, 2023 | finance.yahoo.comSanthera Pharmaceuticals reports 1H resultsSeptember 8, 2023 | seekingalpha.comSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The CornerSeptember 8, 2023 | finance.yahoo.comSanthera Announces Half-Year 2023 Financial Results and Provides Corporate UpdateSeptember 7, 2023 | finance.yahoo.comSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi GroupJuly 31, 2023 | benzinga.comH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)July 31, 2023 | markets.businessinsider.comSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share SplitJune 29, 2023 | finanznachrichten.deSanthera Publishes Timeline of the Reverse Share SplitJune 29, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General MeetingJune 27, 2023 | finanznachrichten.deShareholders Approve all Board Proposals at Today’s Annual General MeetingJune 27, 2023 | finance.yahoo.comCatalyst (CPRX) to Gain DMD Drug Licensing Rights From SantheraJune 21, 2023 | msn.comCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera PharmaceuticalsJune 20, 2023 | finance.yahoo.comSanthera Grants North America License For Vamorolone To Catalyst PharmaJune 20, 2023 | markets.businessinsider.comSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus RoyaltiesJune 20, 2023 | finance.yahoo.comSanthera Publishes Agenda for its Annual General MeetingJune 6, 2023 | finance.yahoo.comSanthera Pharmaceuticals GAAP EPS of -CHF1.17June 2, 2023 | seekingalpha.comSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022June 1, 2023 | finanznachrichten.deSanthera Publishes Annual Report 2022May 31, 2023 | finance.yahoo.comSanthera -- A Duchenne Drug With Positive Study Results That Few Know AboutMay 24, 2023 | thestreet.comSanthera Drug Wins European Approval for Rare Blindness DiseaseMay 13, 2023 | thestreet.comSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate UpdateApril 27, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completedApril 25, 2023 | finanznachrichten.deVamorolone NDA mid-cycle review meeting by FDA completedApril 25, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AG (VTX:SANN) Is Expected To Breakeven In The Near FutureApril 1, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AGMarch 30, 2023 | barrons.comSanthera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular DystrophyMarch 2, 2023 | finance.yahoo.com Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] SPHDF Media Mentions By Week SPHDF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPHDF News Sentiment▼1.140.47▲Average Medical News Sentiment SPHDF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPHDF Articles This Week▼00▲SPHDF Articles Average Week Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News AKBLF News DRTSW News ARNI News ASPHF News ASCLF News AVCTF News AWKNF News AXIM News BRRGF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SPHDF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santhera Pharmaceuticals Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Santhera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
